Works matching AU Yazaki, Paul J.

Results: 38

Bright and Specific Targeting of Metastatic Lymph Nodes in Orthotopic Mouse Models of Gastric Cancer with a Fluorescent Anti-CEA Antibody.

Published in:

Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2025, v. 32, n. 5, p. 3796, doi. 10.1245/s10434-025-16919-4

By:

Cox, Kristin E.;
Amirfakhri, Siamak;
Lwin, Thinzar M.;
Hosseini, Mojgan;
Ghosh, Pradipta;
Obonyo, Marygorret;
Hoffman, Robert M.;
Yazaki, Paul J.;
Bouvet, Michael

Publication type:

Article

ASO Visual Abstract: Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody.

Published in:

2024

By:

Cox, Kristin E.;
Turner, Michael A.;
Lwin, Thinzar M.;
Amirfakhri, Siamak;
Kelly, Kaitlyn J.;
Hosseini, Mojgan;
Ghosh, Pradipta;
Obonyo, Marygorret;
Hoffman, Robert M.;
Yazaki, Paul J.;
Bouvet, Michael

Publication type:

Abstract

Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody.

Published in:

Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2024, v. 31, n. 9, p. 6291, doi. 10.1245/s10434-024-15570-9

By:

Cox, Kristin E.;
Turner, Michael A.;
Lwin, Thinzar M.;
Amirfakhri, Siamak;
Kelly, Kaitlyn J.;
Hosseini, Mojgan;
Ghosh, Pradipta;
Obonyo, Marygorret;
Hoffman, Robert M.;
Yazaki, Paul J.;
Bouvet, Michael

Publication type:

Article

Pretargeting with Cucurbituril--Adamantane Host--Guest Pair in Xenograft Models.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 8, p. 1203, doi. 10.2967/jnumed.122.265008

By:

Jallinoja, Vilma I. J.;
Abbriano, Courtney H.;
Bhatt, Kavita;
Kaur, Amritjyot;
Schlyer, David J.;
Yazaki, Paul J.;
Carney, Brandon D.;
Houghton, Jacob L.

Publication type:

Article

Improved Tumor Responses with Sequential Targeted α-Particles Followed by Interleukin 2 Immunocytokine Therapies in Treatment of CEA-Positive Breast and Colon Tumors in CEA Transgenic Mice.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 12, p. 1859, doi. 10.2967/jnumed.122.264126

By:

Minnix, Megan;
Kujawski, Maciej;
Poku, Erasmus;
Yazaki, Paul J.;
Wong, Jeffrey Y.;
Shively, John E.

Publication type:

Article

Improved tumor responses with sequential targeted alpha followed by IL2 immunocytokine therapies in treatment of CEA positive breast and colon tumors in CEA transgenic mice.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264126

By:

Minnix, Megan;
Kujawski, Maciej;
Poku, Erasmus;
Yazaki, Paul J.;
Wong, Jeffrey Y.;
Shively, John E.

Publication type:

Article

Improved tumor responses with sequential targeted alpha followed by IL2 immunocytokine therapies in treatment of CEA positive breast and colon tumors in CEA transgenic mice.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.264126

By:

Minnix, Megan;
Kujawski, Maciej;
Poku, Erasmus;
Yazaki, Paul J.;
Wong, Jeffrey Y.;
Shively, John E.

Publication type:

Article

Improved tumor responses with sequential targeted alpha followed by IL2 immunocytokine therapies in treatment of CEA positive breast and colon tumors in CEA transgenic mice.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.122.264126

By:

Minnix, Megan;
Maciej Kujawski;
Poku, Erasmus;
Yazaki, Paul J.;
Wong, Jeffrey Y.;
Shively, John E.

Publication type:

Article

TAG-72 targeted α-radionuclide therapy of ovarian cancer using actinium- 225 labeled DOTAylated-huCC49 antibody.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.243394

By:

Minnix, Megan;
Lin Li;
Yazaki, Paul J.;
Miller, Aaron D.;
Chea, Junie;
Poku, Erasmus;
An Liu;
Wong, Jeffrey Y. C.;
Rockne, Russell C.;
Colcher, David;
Shively, John E.

Publication type:

Article

TAG-72 targeted α-radionuclide therapy of ovarian cancer using actinium- 225 labeled DOTAylated-huCC49 antibody.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.243394

By:

Minnix, Megan;
Lin Li;
Yazaki, Paul J.;
Miller, Aaron D.;
Junie Chea;
Poku, Erasmus;
An Liu;
Wong, Jeffrey Y. C.;
Rockne, Russell C.;
Colcher, David;
Shively, John E.

Publication type:

Article

TAG-72 targeted α-radionuclide therapy of ovarian cancer using actinium225 labeled DOTAylated-huCC49 antibody.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.120.243394

By:

Minnix, Megan;
Lin Li;
Yazaki, Paul J.;
Miller, Aaron D.;
Junie Chea;
Poku, Erasmus;
An Liu;
Wong, Jeffrey Y. C.;
Rockne, Russell C.;
Colcher, David;
Shively, John E.

Publication type:

Article

TAG-72 targeted α-radionuclide therapy of ovarian cancer using actinium-225 labeled DOT Aylated-hu CC49 antibody.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.120.243394

By:

Minnix, Megan;
Lin Li;
Yazaki, Paul J.;
Miller, Aaron D.;
Chea, Junie;
Poku, Erasmus;
Liu, An;
Wong, Jeffrey Y. C.;
Rockne, Russell C.;
Colcher, David;
Shively, John E.

Publication type:

Article

TAG-72 targeted α-radionuclide therapy of ovarian cancer using actinium-225 labeled DOTAylated-huCC49 antibody.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.120.243394

By:

Megan Minnix;
Lin Li;
Yazaki, Paul J.;
Miller, Aaron D.;
Junie Chea;
Poku, Erasmus;
An Liu;
Wong, Jeffrey Y. C.;
Rockne, Russell C.;
Colcher, David;
Shively, John E.

Publication type:

Article

Quantitative ImmunoPET of Prostate Cancer Xenografts with 89Zr- and 124I-Labeled Anti-PSCA A11 Minibody.

Published in:

Journal of Nuclear Medicine, 2014, v. 55, n. 3, p. 452, doi. 10.2967/jnumed.113.120873

By:

Knowles, Scott M.;
Zettlitz, Kirstin A.;
Tavaré, Richard;
Rochefort, Matthew M.;
Salazar, Felix B.;
Stout, David B.;
Yazaki, Paul J.;
Reiter, Robert E.;
Wu, Anna M.

Publication type:

Article

Monodispersed DOTA-PEG-Conjugated Anti-TAG-72 Diabody Has Low Kidney Uptake and High Tumor-to-Blood Ratios Resulting in Improved 64Cu PET.

Published in:

Journal of Nuclear Medicine, 2010, v. 51, n. 7, p. 1139, doi. 10.2967/jnumed.109.074153

By:

Lin Li;
Turatti, Fabio;
Crow, Desiree;
Bading, James R.;
Anderson, Anne-Line;
Poku, Erasmus;
Yazaki, Paul J.;
Williams, Lawrence E.;
Tamvakis, Debra;
Sanders, Paul;
Leong, David;
Raubitschek, Andrew;
Hudsony, Peter J.;
Colchery, David;
Shively, John E.

Publication type:

Article

124I-Labeled Engineered Anti-CEA Minibodies and Diabodies Allow High-Contrast, Antigen-Specific Small-Animal PET Imaging of Xenografts in Athymic Mice.

Published in:

Journal of Nuclear Medicine, 2003, v. 44, n. 12, p. 1962

By:

Sundaresan, Gobalakrishnan;
Yazaki, Paul J.;
Shively, John E.;
Finn, Ronald D.;
Larson, Steven M.;
Raubitschek, Andrew A.;
Williams, Lawrence E.;
Chatziioannou, Arion F.;
Gambhir, Sanjiv S.;
Wu, Anna M.

Publication type:

Article

Development of Anti-CEA CH2 Domain-Deleted Antibody (M5A∆CH2) for the PET Imaging of Colorectal Cancer.

Published in:

Molecular Imaging & Biology, 2025, v. 27, n. 2, p. 192, doi. 10.1007/s11307-025-01997-3

By:

Jitender, Jitender;
Hong, Teresa;
Sherman, Anakim;
Wong, Patty;
Aniogo, Eric;
Kujawski, Maciej;
Shively, John E.;
Yazaki, Paul J.

Publication type:

Article

Multimodality PET and Near-Infrared Fluorescence Intraoperative Imaging of CEA-Positive Colorectal Cancer.

Published in:

Molecular Imaging & Biology, 2023, v. 25, n. 4, p. 727, doi. 10.1007/s11307-023-01831-8

By:

Lwin, Thinzar M.;
Minnix, Megan;
Li, Lin;
Sherman, Anakim;
Hong, Teresa;
Wong, Jeffery Y. C.;
Olafsen, Tove;
Poku, Erasmus;
Bouvet, Michael;
Fong, Yuman;
Shively, John E.;
Yazaki, Paul J.

Publication type:

Article

Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.

Published in:

OncoImmunology, 2021, v. 10, n. 1, p. 1, doi. 10.1080/2162402X.2021.1899469

By:

Cha, Seung E.;
Kujawski, Maciej;
Yazaki, Paul J.;
Brown, Christine;
Shively, John E.

Publication type:

Article

Comparison of IL‐2‐antibody to IL‐2‐Fc with or without stereotactic radiation therapy in CEA immunocompetent mice with CEA positive tumors.

Published in:

Cancer Medicine, 2024, v. 13, n. 3, p. 1, doi. 10.1002/cam4.6909

By:

Williams, Lindsay;
Li, Lin;
Yazaki, Paul J.;
Wong, Patty;
Hong, Teresa;
Poku, Erasmus K.;
Hui, Susanta;
Ghimire, Hemendra;
Shively, John E.;
Kujawski, Maciej

Publication type:

Article

The Use of Fluorescent Anti-CEA Antibodies to Label, Resect and Treat Cancers: A Review.

Published in:

Biomolecules (2218-273X), 2021, v. 11, n. 12, p. 1819, doi. 10.3390/biom11121819

By:

Turner, Michael A.;
Lwin, Thinzar M.;
Amirfakhri, Siamak;
Nishino, Hiroto;
Hoffman, Robert M.;
Yazaki, Paul J.;
Bouvet, Michael

Publication type:

Article

In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.849338

By:

Mohajershojai, Tabassom;
Jha, Preeti;
Boström, Anna;
Frejd, Fredrik Y.;
Yazaki, Paul J.;
Nestor, Marika

Publication type:

Article

Targeting CEA in metastatic triple negative breast cancer with image-guided radiation followed by Fab-mediated chimeric antigen receptor (CAR) T-cell therapy.

Published in:

Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2024.1499471

By:

Aniogo, Eric;
Kujawski, Maciej;
Awuah, Dennis;
Cha, Seung E.;
Espinosa, Ruby;
Hui, Susanta;
Ghimire, Hemendra;
Yazaki, Paul J.;
Brown, Christine E.;
Wang, Xiuli;
Shively, John E.

Publication type:

Article

Generation of IL‐2‐Fc‐antibody conjugates by click chemistry.

Published in:

Biotechnology Journal, 2023, v. 18, n. 9, p. 1, doi. 10.1002/biot.202300115

By:

Williams, Lindsay;
Li, Lin;
Yazaki, Paul J.;
Wong, Patty;
Miller, Aaron;
Hong, Teresa;
Poku, Erasmus K.;
Bhattacharya, Supriyo;
Shively, John E.;
Kujawski, Maciej

Publication type:

Article

T‐cell surface generation of dual bivalent, bispecific T‐cell engaging, RNA duplex cross‐linked antibodies (dbBiTERs) for re‐directed tumor cell lysis.

Published in:

Biotechnology Journal, 2022, v. 17, n. 2, p. 1, doi. 10.1002/biot.202100389

By:

Kujawski, Maciej;
Li, Lin;
Li, Harry;
Yazaki, Paul J.;
Swiderski, Piotr;
Shively, John E.

Publication type:

Article

Truncation of blood curves to enhance imaging and therapy with monoclonal antibodies.

Published in:

Medical Physics, 2000, v. 27, n. 5, p. 988, doi. 10.1118/1.598963

By:

Williams, Lawrence E.;
Liu, An;
Wu, Anna M.;
Yazaki, Paul J.;
Yamauchi, Dave M.;
Lopatin, George;
Raubitschek, Andrew A.;
Wong, Jeffrey Y. C.

Publication type:

Article

Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors.

Published in:

EJNMMI Research, 2020, v. 10, n. 1, p. 1, doi. 10.1186/s13550-020-0600-z

By:

Bäck, Tom A.;
Jennbacken, Karin;
Hagberg Thulin, Malin;
Lindegren, Sture;
Jensen, Holger;
Olafsen, Tove;
Yazaki, Paul J.;
Palm, Stig;
Albertsson, Per;
Damber, Jan-Erik;
Wu, Anna M.;
Welén, Karin

Publication type:

Article

Development and Potent Anti-Tumor Activity of a Fully Humanized Anti-TAG-72-IL-2 Fusion Protein for Therapy of Solid Tumors.

Published in:

Cancers, 2025, v. 17, n. 9, p. 1453, doi. 10.3390/cancers17091453

By:

Aniogo, Eric;
Williams, Lindsay;
Hong, Teresa;
Wong, Patty;
Hui, Susanta K.;
Ghimire, Hemendra;
Poku, Erasmus K.;
Colcher, David M.;
Yazaki, Paul J.;
Shively, John E.;
Kujawski, Maciej

Publication type:

Article

Accurate Co-Localization of Luciferase Expression and Fluorescent Anti-CEA Antibody Targeting of Liver Metastases in an Orthotopic Mouse Model of Colon Cancer.

Published in:

Cancers, 2024, v. 16, n. 19, p. 3341, doi. 10.3390/cancers16193341

By:

Lee, Kyung-Ha;
Cox, Kristin E.;
Amirfakhri, Siamak;
Jaiswal, Sunidhi;
Liu, Shanglei;
Hosseini, Mojgan;
Lwin, Thinzar M.;
Yazaki, Paul J.;
Hoffman, Robert M.;
Bouvet, Michael

Publication type:

Article

Enhanced Therapeutic Effects of 177 Lu-DOTA-M5A in Combination with Heat Shock Protein 90 Inhibitor Onalespib in Colorectal Cancer Xenografts.

Published in:

Cancers, 2023, v. 15, n. 17, p. 4239, doi. 10.3390/cancers15174239

By:

Mohajershojai, Tabassom;
Spangler, Douglas;
Chopra, Saloni;
Frejd, Fredrik Y.;
Yazaki, Paul J.;
Nestor, Marika

Publication type:

Article

Improved antibody-guided surgery with a near-infrared dye on a pegylated linker for CEA-positive tumors.

Published in:

Journal of Biomedical Optics, 2019, v. 24, n. 6, p. 66012, doi. 10.1117/1.JBO.24.6.066012

By:

Yazaki, Paul J.;
Lwin, Thinzar M.;
Minnix, Megan;
Li, Lin;
Sherman, Anakim;
Molnar, Justin;
Miller, Aaron;
Frankel, Paul;
Chea, Junie;
Poku, Erasmus;
Bowles, Nicole;
Hoffman, Robert M.;
Shively, John E.;
Bouvet, Michael

Publication type:

Article

Neural Stem Cells as a Novel Platform for Tumor-Specific Delivery of Therapeutic Antibodies.

Published in:

PLoS ONE, 2009, v. 4, n. 12, p. 1, doi. 10.1371/journal.pone.0008314

By:

Frank, Richard T.;
Edmiston, Marissa;
Kendall, Stephen E.;
Najbauer, Joseph;
Chia-Wei Cheung;
Kassa, Thewodros;
Metz, Marianne Z.;
Kim, Seung U.;
Glackin, Carlotta A.;
Wu, Anna M.;
Yazaki, Paul J.;
Aboody, Karen S.

Publication type:

Article

Humanized Fluorescent Tumor-associated Glycoprotein-72 Antibody Selectively Labels Colon-cancer Liver Metastases in Orthotopic Mouse Models.

Published in:

In Vivo, 2020, v. 34, n. 5, p. 2303, doi. 10.21873/invivo.12042

By:

HOLLANDSWORTH, HANNAH M.;
HIROTO NISHINO;
TURNER, MICHAEL;
AMIRFAKHRI, SIAMAK;
FILEMONI, FILEMONI;
HOFFMAN, ROBERT M.;
YAZAKI, PAUL J.;
BOUVET, MICHAEL

Publication type:

Article

A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.

Published in:

PEDS: Protein Engineering, Design & Selection, 2013, v. 26, n. 3, p. 187, doi. 10.1093/protein/gzs096

By:

Yazaki, Paul J.;
Lee, Brian;
Channappa, Divya;
Cheung, Chia-Wei;
Crow, Desiree;
Chea, Junie;
Poku, Erasmus;
Li, Lin;
Andersen, Jan Terje;
Sandlie, Inger;
Orcutt, Kelly Davis;
Wittrup, K.Dane;
Shively, John E.;
Raubitschek, Andrew;
Colcher, David

Publication type:

Article

Humanization of the anti-CEA T84.66 antibody based on crystal structure data.

Published in:

PEDS: Protein Engineering, Design & Selection, 2004, v. 17, n. 5, p. 481, doi. 10.1093/protein/gzh056

By:

Paul J. Yazaki;
John E. Shively;
David Ikle;
Lawrence E. Williams;
Jeffrey Y.C. Wong;
David Colcher;
Anna M. Wu;
Andrew A. Raubitschek

Publication type:

Article

Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting.

Published in:

PEDS: Protein Engineering, Design & Selection, 2004, v. 17, n. 4, p. 315, doi. 10.1093/protein/gzh040

By:

Olafsen, Tove;
Tan, Giselle J.;
Cheung, Chia-wei;
Yazaki, Paul J.;
Park, Jinha M.;
Shively, John E.;
Williams, Lawrence E.;
Raubitschek, Andrew A.;
Press, Michael F.;
Wu, Anna M.

Publication type:

Article

Covalent disulfide‐linked anti‐CEA diabody allows site‐specific conjugation and radiolabeling for tumor targeting applications.

Published in:

PEDS: Protein Engineering, Design & Selection, 2004, v. 17, n. 1, p. 21, doi. 10.1093/protein/gzh009

By:

Tove Olafsen;
Chia‐wei Cheung;
Paul J. Yazaki;
Lin Li;
Gobalakrishnan Sundaresan;
Sanjiv S. Gambhir;
Mark A. Sherman;
Lawrence E. Williams;
John E. Shively;
Andrew A. Raubitschek;
Anna M. Wu

Publication type:

Article

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.

Published in:

Nature, 2015, v. 517, n. 7534, p. 386, doi. 10.1038/nature13848

By:

Huang, Yu-Hwa;
Zhu, Chen;
Kondo, Yasuyuki;
Anderson, Ana C.;
Gandhi, Amit;
Russell, Andrew;
Dougan, Stephanie K.;
Petersen, Britt-Sabina;
Melum, Espen;
Pertel, Thomas;
Clayton, Kiera L.;
Raab, Monika;
Chen, Qiang;
Beauchemin, Nicole;
Yazaki, Paul J.;
Pyzik, Michal;
Ostrowski, Mario A.;
Glickman, Jonathan N.;
Rudd, Christopher E.;
Ploegh, Hidde L.

Publication type:

Article

Works matching AU Yazaki, Paul J.

Bright and Specific Targeting of Metastatic Lymph Nodes in Orthotopic Mouse Models of Gastric Cancer with a Fluorescent Anti-CEA Antibody.

ASO Visual Abstract: Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody.

Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody.

Pretargeting with Cucurbituril--Adamantane Host--Guest Pair in Xenograft Models.

Improved Tumor Responses with Sequential Targeted α-Particles Followed by Interleukin 2 Immunocytokine Therapies in Treatment of CEA-Positive Breast and Colon Tumors in CEA Transgenic Mice.

Improved tumor responses with sequential targeted alpha followed by IL2 immunocytokine therapies in treatment of CEA positive breast and colon tumors in CEA transgenic mice.

Improved tumor responses with sequential targeted alpha followed by IL2 immunocytokine therapies in treatment of CEA positive breast and colon tumors in CEA transgenic mice.

Improved tumor responses with sequential targeted alpha followed by IL2 immunocytokine therapies in treatment of CEA positive breast and colon tumors in CEA transgenic mice.

TAG-72 targeted α-radionuclide therapy of ovarian cancer using actinium- 225 labeled DOTAylated-huCC49 antibody.

TAG-72 targeted α-radionuclide therapy of ovarian cancer using actinium- 225 labeled DOTAylated-huCC49 antibody.

TAG-72 targeted α-radionuclide therapy of ovarian cancer using actinium225 labeled DOTAylated-huCC49 antibody.

TAG-72 targeted α-radionuclide therapy of ovarian cancer using actinium-225 labeled DOT Aylated-hu CC49 antibody.

TAG-72 targeted α-radionuclide therapy of ovarian cancer using actinium-225 labeled DOTAylated-huCC49 antibody.

Quantitative ImmunoPET of Prostate Cancer Xenografts with <sup>89</sup>Zr- and <sup>124</sup>I-Labeled Anti-PSCA A11 Minibody.

Monodispersed DOTA-PEG-Conjugated Anti-TAG-72 Diabody Has Low Kidney Uptake and High Tumor-to-Blood Ratios Resulting in Improved <sup>64</sup>Cu PET.

<sup>124</sup>I-Labeled Engineered Anti-CEA Minibodies and Diabodies Allow High-Contrast, Antigen-Specific Small-Animal PET Imaging of Xenografts in Athymic Mice.

Development of Anti-CEA C<sub>H</sub>2 Domain-Deleted Antibody (M5A∆C<sub>H</sub>2) for the PET Imaging of Colorectal Cancer.

Multimodality PET and Near-Infrared Fluorescence Intraoperative Imaging of CEA-Positive Colorectal Cancer.

Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.

Comparison of IL‐2‐antibody to IL‐2‐Fc with or without stereotactic radiation therapy in CEA immunocompetent mice with CEA positive tumors.

The Use of Fluorescent Anti-CEA Antibodies to Label, Resect and Treat Cancers: A Review.

In Vitro Characterization of <sup>177</sup>Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.

Targeting CEA in metastatic triple negative breast cancer with image-guided radiation followed by Fab-mediated chimeric antigen receptor (CAR) T-cell therapy.

Generation of IL‐2‐Fc‐antibody conjugates by click chemistry.

T‐cell surface generation of dual bivalent, bispecific T‐cell engaging, RNA duplex cross‐linked antibodies (dbBiTERs) for re‐directed tumor cell lysis.

Truncation of blood curves to enhance imaging and therapy with monoclonal antibodies.

Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors.

Development and Potent Anti-Tumor Activity of a Fully Humanized Anti-TAG-72-IL-2 Fusion Protein for Therapy of Solid Tumors.

Accurate Co-Localization of Luciferase Expression and Fluorescent Anti-CEA Antibody Targeting of Liver Metastases in an Orthotopic Mouse Model of Colon Cancer.

Enhanced Therapeutic Effects of 177 Lu-DOTA-M5A in Combination with Heat Shock Protein 90 Inhibitor Onalespib in Colorectal Cancer Xenografts.

Improved antibody-guided surgery with a near-infrared dye on a pegylated linker for CEA-positive tumors.

Neural Stem Cells as a Novel Platform for Tumor-Specific Delivery of Therapeutic Antibodies.

Humanized Fluorescent Tumor-associated Glycoprotein-72 Antibody Selectively Labels Colon-cancer Liver Metastases in Orthotopic Mouse Models.

A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.

Humanization of the anti-CEA T84.66 antibody based on crystal structure data.

Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting.

Covalent disulfide‐linked anti‐CEA diabody allows site‐specific conjugation and radiolabeling for tumor targeting applications.

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.